Munich - Delayed Quote EUR

Hansa Biopharma AB (24H.MU)

1.9830

0.0000

(0.00%)

At close: April 17 at 8:02:20 AM GMT+2

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

Hansa Biopharma AB, 'Hansa' (Nasdaq Stockholm: HNSA), announced today that it has completed enrolment of its 20-HMedIdeS-19 Post Authorization Efficacy and Safety (PAES) study, an open-label Phase 3 confirmatory study in Europe investigating the one-year patient and graft survival in highly sensitized patients who have undergone HLA-incompatible kidney transplantation following desensitization treatment with imlifidase. Imlifidase is the Company's first generation, first-in-class, one-time treat

PR Newswire last month

HNSBF
Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results

Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced its full year and Q4 2024 financial results.

PR Newswire 2 months ago

HNSBF
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare Conference. If you are interested in a meeting, please contact Hansa Biopharma at ir@hansabiopharma.com.

PR Newswire 3 months ago

HNSBF
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome

Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS.

PR Newswire 3 months ago

HNSBF
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease

Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease. Anti-GBM is a rare, severe autoimmune condition affecting around 1.6 people per million annually.1 Imlifidase has been granted orphan drug designation for the treatment of anti-GBM disease by both the U.S. FDA and the European Medicines Agency (EMA). Enrolment completion was

PR Newswire 4 months ago

HNSBF
Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome

LUND, Sweden & EVRY, France, December 03, 2024--This is a crucial step in order to make gene therapy more effective and to increase the number of patients able to access it.

Business Wire 4 months ago

HNSBF
Hansa Biopharma to Attend Truist Securities BioPharma Symposium

Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York, NY. Hitto Kaufmann, Chief R&D Officer at the Company will participate in a panel discussion entitled, 'Inflammatory Insights: Advancing Novel Therapeutics Across Autoimmune and Inflammatory Indications' on Thursday November 7th from 10:30 to 11:20 AM EST.

PR Newswire 5 months ago

HNSBF
Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results

Hansa Biopharma today announced its interim report for January-September and third quarter 2024 financial results.

PR Newswire 5 months ago

HNSBF
Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial

Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next generation immunoglobulin G (IgG)-cleaving molecule, assessing IgG recovery, immunogenicity and redosing potential.

PR Newswire 6 months ago

HNSBF
Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Hansa Biopharma today announced that Søren Tulstrup will participate in a Fireside chat hosted by Douglas Tsao, Managing Director and Senior Financial Analyst at H.C. Wainwright on Wednesday, September 11 at 8:00 AM EST. Mr. Tsao's research focuses on biopharmaceuticals and specialty pharmaceuticals. The company will cover Hansa's clinical stage programs, recent performance and upcoming milestones.

PR Newswire 7 months ago

HNSBF
Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis

Hansa Biopharma AB, ("Hansa" or the "Company") (Nasdaq Stockholm: HNSA), today announced that Matthew Shaulis, Chief Commercial Officer and US President has decided to leave the company in late September. Effective immediately, the Commercial Leadership team will report to Søren Tulstrup, President and CEO. A search is underway for a new CCO and US President.

PR Newswire 7 months ago

HNSBF
Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update

Hansa Biopharma today announced its first half and second quarter 2024 financial results and business update.

PR Newswire 8 months ago

HNSBF
Hansa Biopharma to host Q2 2024 interim results conference call

Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), will publish its interim report for January-June 2024 on July 18, 2024. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST/8:00 AM EST. The event will be hosted by Søren Tulstrup, President and CEO, Matthew Shaulis, CCO and US President, Evan Ballantyne, CFO, and Hitto Kaufmann, CR&DO. The call will include a review of the interim results and a business and pipeline update. It will be held in Engli

PR Newswire 9 months ago

HNSBF
Hansa Biopharma: increase in number of shares and votes

Hansa Biopharma AB, ("Hansa Biopharma" or the "Company") (NASDAQ: HNSA) (STOCKHOLM: HNSA) today announced that Hansa's registered share capital and number of shares and votes have increased through (i) the issue of 2,305,260 new ordinary shares resolved on 12 April 2024 and registered with the Swedish Companies Registration Office during June 2024, whereby the number of votes increased with 2,305,260 and the share capital increased with SEK 2,305,260, and (ii) conversion of all 2,362,445 issued

PR Newswire 9 months ago

HNSBF
Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial

Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ Stockholm: HNSA), today announced recruitment and randomization in its US ConfIdeS trial is complete. ConfIdeS is a pivotal Phase 3 open label, randomized, controlled trial of imlifidase in kidney transplantation. Data from the trial is expected to support a Biologic License Application (BLA) submission under the accelerated approval pathway to the US Food and Drug Administration (FDA) in the second half of 2025.

PR Newswire 10 months ago

HNSBF
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting

. Hansa Biopharma, "Hansa" (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be presented at the American Transplant Congress (ATC), the joint annual meeting of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (ATS). Imlifidase is Hansa's unique antibody-cleaving enzyme that specifically targets IgG and inhibits IgG-mediated immune response.1

PR Newswire 10 months ago

HNSBF

Performance Overview

Return	24H.MU	OMX Stockholm 30 Index (^OMX)
YTD	-43.63%	-5.14%
1-Year	-20.55%	-5.98%
3-Year	-67.03%	+12.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hansa Biopharma AB (24H.MU)

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome

Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease

Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome

Hansa Biopharma to Attend Truist Securities BioPharma Symposium

Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results

Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial

Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis

Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update

Hansa Biopharma to host Q2 2024 interim results conference call

Hansa Biopharma: increase in number of shares and votes

Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial

Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting

Performance Overview